Nootropic Peptides.

Nootropic peptides — peptides with potential cognitive-enhancing or neuroprotective effects — represent one of the more intriguing frontiers in peptide research. Several compounds have shown genuine neurological effects in clinical settings, particularly in Russian and Eastern European medical practice, while others remain at the preclinical stage with dramatic animal data but no human validation. Semax is a synthetic heptapeptide analog of ACTH(4-10), the adrenocorticotropic hormone fragment responsible for cognitive effects without adrenal stimulation. It is one of the few nootropic peptides with legitimate clinical use — approved in Russia and Ukraine for conditions including stroke recovery, cognitive impairment, and optic nerve disease. Semax upregulates brain-derived neurotrophic factor (BDNF), a key protein for neuronal growth and synaptic plasticity. Clinical studies (primarily Russian) have shown improved cognitive function, faster stroke recovery, and enhanced attention and memory. It is administered intranasally, which is convenient and provides rapid CNS delivery. The evidence base is stronger than most nootropic peptides, though the lack of Western clinical trials limits broader acceptance. Selank is a synthetic heptapeptide analog of tuftsin, an endogenous immune-regulating peptide. It was developed at the Institute of Molecular Genetics in Russia and is approved there as an anxiolytic with nootropic properties. Selank modulates GABA and serotonin systems, reduces anxiety without sedation, and has shown cognitive-enhancing effects in clinical studies. It is also administered intranasally. Users report reduced anxiety, improved focus, and enhanced verbal fluency. While the Russian clinical data is more extensive than what exists for most research peptides, the same limitation applies — limited Western replication. Cerebrolysin is a porcine brain-derived peptide mixture containing neurotrophic factors. Unlike most peptides discussed in biohacking circles, cerebrolysin has a relatively substantial clinical evidence base for traumatic brain injury (TBI), stroke recovery, and vascular dementia, with studies published in international (not only Russian) journals. It is administered intravenously, which limits self-administration. Clinical trials have shown improved neurological outcomes in stroke patients and cognitive improvements in dementia. It is used clinically in over 40 countries, though not FDA-approved in the US. Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV analog that has generated enormous interest due to its extreme potency in animal models — it was described as seven orders of magnitude more potent than BDNF at forming new synaptic connections in rat models. The cognitive enhancement in animal studies was dramatic. However, dihexa has zero published human clinical trial data. Its extreme potency is as much a safety concern as it is a reason for excitement. Without human dosing studies, the risk profile is completely unknown. This is one of the most speculative nootropic peptides, and the gap between animal promise and human evidence is vast. Pinealon is a tripeptide bioregulator (Glu-Asp-Arg) developed by the Russian Institute of Bioregulation and Gerontology. It is claimed to regulate pineal gland function and have neuroprotective effects. However, the evidence base is extremely thin, consisting primarily of publications from the developing lab with limited independent replication. It represents the weakest evidence tier among commonly discussed nootropic peptides. Honest assessment: Semax and selank have the most meaningful human evidence, with actual clinical approval in Russia based on clinical studies. Cerebrolysin has a legitimate international clinical evidence base for neurological conditions. Dihexa has spectacular animal data but zero human evidence. Pinealon has minimal evidence from any source. For cognitive enhancement, the evidence gradient matters enormously.